Literature DB >> 27102819

Frequency of complications and the effects of pneumococcal vaccination in young children with acute respiratory tract infection.

Juliana R Oliveira1, Maiara L Bouzas2, Maria-Regina A Cardoso3, Aldina Barral4, Cristiana Nascimento-Carvalho5.   

Abstract

BACKGROUND: Acute respiratory infection (ARI) is the most frequent reason for children being seen by doctors worldwide. We aimed to estimate the frequency of complications in children aged 6-23 months during ARI episode and to evaluate risk factors present on recruitment associated with complications after the universal implementation of pneumococcal vaccine (PCV10) in our region.
METHODS: This prospective cohort enrolled children who had shown ARI for up to 7 days and who were subsequently followed up 14-21 days after, in Salvador, Brazil. Data on recruitment were registered. The vaccine card was personally checked. Complication was defined when hospitalization, pneumonia or acute otitis media (AOM) were informed during the follow-up visit. Pneumonia and AOM were diagnosed by a doctor. Multiple logistic regression analysis was performed.
RESULTS: Of 576 children, 422 (73%) returned and 79 (19%; 95%CI: 15-23%) had complications. The mean interval between admission and follow-up was 23±13 days. Pneumonia (n=47; 11%), hospitalization (n=28; 7%), and AOM (n=17; 4%) were reported. Most of the patients presented one complication (n=66; 84%) followed by two (n=13; 16%). Report of fever (92% versus 79%; OR [95%CI]: 2.90 [1.18-7.14]), bird at home (24% versus 14%; OR [95%CI]: 2.13 [1.07-4.26]), ronchi (48% versus 36%; OR [95%CI]: 2.06 [1.16-3.67]) or crackles (17% versus 7%; OR [95%CI]: 2.36 [1.04-5.38]) on auscultation were directly associated with complications whereas PCV10 (59% versus 75%; OR [95%CI]: 0.46 [0.26-0.82]) was inversely associated. Bird at home (OR [95%CI]: 5.80 [1.73-19.38]) and ronchi (OR [95%CI]: 6.39 [1.96-20.85]) were associated with AOM; PCV10 was inversely associated with AOM (OR [95%CI]: 0.16 [0.05-0.52]). Crackles were associated with pneumonia (OR [95%CI]: 2.55 [1.01-6.40]).
CONCLUSIONS: One fifth of the children presented complications. PCV10 was independently associated with lower odds of development of AOM. Bird at home and ronchi are risk factors of otitis. Crackles are associated with pneumonia.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Children; Common cold; Pneumococcal conjugate vaccine; Viruses

Mesh:

Substances:

Year:  2016        PMID: 27102819     DOI: 10.1016/j.vaccine.2016.04.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil.

Authors:  Ana L Sartori; Ruth Minamisava; Ana L Bierrenbach; Cristiana M Toscano; Eliane T Afonso; Otaliba L Morais-Neto; José L F Antunes; Elier B Cristo; Ana Lucia Andrade
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

2.  Effectiveness and safety of Danmu extract syrup for acute upper respiratory tract infection in children: A real-world, prospective cohort study.

Authors:  Linan Zeng; Hailong Li; Chuan Zhang; Deying Kang; Guanjian Liu; Xihong Li; Lina Chen; Min Zeng; Liang Huang; Peipei Xu; Shiyin Feng; Qin Yu; Hanmin Liu; Lingli Zhang
Journal:  J Evid Based Med       Date:  2022-03

3.  The yield of respiratory viruses detection testing is age-dependent in children with acute otitis media.

Authors:  Tal Marom; Avital Fellner; Ze'ev Hirschfeld; Tzilia Lazarovitch; Haim Gavriel; Limor Muallem-Kalmovich; Jacob Pitaro
Journal:  Ther Adv Infect Dis       Date:  2019-11-19

4.  Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.

Authors:  Adriana Guzman-Holst; Eliana de Barros; Pilar Rubio; Rodrigo DeAntonio; Otavio Cintra; Ariane Abreu
Journal:  Hum Vaccin Immunother       Date:  2021-03-18       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.